Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 2,486 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Results available

AZD1775 for Advanced Solid Tumors

NCT01748825
Conditions
Solid Tumors
Interventions
MK-1775 (AZD1775)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions
rezatapopt, pembrolizumab
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 26 more
Conditions
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer, Prostate Cancer, Urothelial Carcinoma, Colorectal Cancer, Triple Negative Breast Cancer, High Grade Ovarian Serous Adenocarcinoma, Diffuse Large B Cell Lymphoma, Renal Cell Cancer Metastatic
Interventions
ZM008
Biological
Lead sponsor
Zumutor Biologics Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Austin, TX 78758, Texas • San Antonio, Texas
Conditions
Neoplasm Metastasis, Carcinoma
Interventions
Paclitaxel plus PTK787
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Cancer
Interventions
PFK-158
Drug
Lead sponsor
Advanced Cancer Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Louisville, Kentucky • Houston, Texas + 1 more
Conditions
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma
Interventions
DM005
Drug
Lead sponsor
Doma Biopharmaceutical(Suzhou)Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Detroit, Michigan • Dallas, Texas • Fairfax, Virginia
Conditions
Advanced Solid Tumors, Non-small Cell Lung Cancer
Interventions
AMG 479, Everolimus, Panitumumab
Drug
Lead sponsor
Jeffrey Clarke
Other
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
HER2 Negative Metastatic Breast Cancer
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Tumors, Hodgkins Disease, Non-Hodgkins Lymphoma
Interventions
VLI
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer, Soft Tissue Sarcoma
Interventions
AVA6000
Drug
Lead sponsor
Avacta Life Sciences Ltd
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
New York, New York • Houston, Texas • Seattle, Washington
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
oblimersen sodium, docetaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
Interventions
FT500, Nivolumab, Pembrolizumab, Atezolizumab, Cyclophosphamide, Fludarabine, IL-2
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more
Conditions
Advanced Malignant Solid Neoplasm
Interventions
Dinaciclib, Veliparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Platinum Responsive Malignancies
Interventions
KML-001, Cisplatin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Advanced Cancer, Lymphoma
Interventions
NC-4016
Drug
Lead sponsor
NanoCarrier Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Advanced Solid Tumors, Ovarian Cancer, Breast Cancer
Interventions
SY-1365 (Part 1), Carboplatin, Fulvestrant, SY-1365 (Cohort 2), SY-1365 (Cohort 5), SY-1365 (Part 2 Single Agent)
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Francisco, California + 11 more
Conditions
Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
Ezabenlimab, BI 754111
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Miami, Florida • Sarasota, Florida • Hackensack, New Jersey + 3 more
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
alvespimycin hydrochloride
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
alvocidib, docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
Interventions
SY-5609, Fulvestrant, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 11 more
Conditions
Advanced Cancers, Solid Tumors
Interventions
Pazopanib, Everolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Sarcoma, Colorectal Cancer, Head and Neck Cancer, Cancer of Unknown Primary, Bladder Cancer, Ovarian Cancer
Interventions
Carboplatin, Cisplatin, Palbociclib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Cancer, Solid Tumors
Interventions
CBP501 and Cisplatin
Drug
Lead sponsor
CanBas Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Las Vegas, Nevada